Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Status:
Completed
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in
a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in
which further therapeutic development will be performed. Extensive biological- and
immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct
processes responsible for the breakdown of immunological tolerance in these pathologies and
(ii) to discover potential biomarkers of the IL2 response.